Despite generic industry requests for FDA to allow flexibility in generic product design, the agency declined to make any major modifications to its draft guidance on the size, shape and other physical characteristics of generic tablets and capsules.
The Generic Pharmaceutical Association and Mylan Inc. had advised the agency that manufacturers make generic drugs larger than the brand to get around the brand’s design patents